Comparative Pharmacology
Head-to-head clinical analysis: IBUPROHM COLD AND SINUS versus NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROHM COLD AND SINUS versus NAPROSYN.
IBUPROHM COLD AND SINUS vs NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors in nasal mucosa, reducing nasal congestion.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum daily dose: 6 tablets (ibuprofen 1200 mg, pseudoephedrine 180 mg).
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
1.8–2.5 hours in adults; prolonged to 3–4 hours in elderly or hepatic impairment due to reduced clearance.
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with approximately 1% excreted as unchanged ibuprofen. Biliary/fecal excretion is <10%.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Category C
Category C
NSAID/Decongestant Combination
NSAID